What is the current PD-1 and PD-L1 Drug market size?

The current market size is approximately USD 20 billion as of 2022, driven by increasing demand.

What is the growth forecast for the PD-1 and PD-L1 Drug market?

The market is expected to grow at a CAGR of 13.8% from 2023 to 2028, driven by rising cancer cases.

What are the key drivers of the PD-1 and PD-L1 Drug market?

Key drivers include increasing cancer prevalence, rising awareness, and growing adoption of immunotherapy treatments.

What are the major challenges facing the PD-1 and PD-L1 Drug market?

Challenges include high development costs, intense competition, and regulatory hurdles in the future outlook.

Which regions are leading the PD-1 and PD-L1 Drug market?

North America and Europe are leading the market, driven by strong healthcare infrastructure and high adoption rates.

Who are the top companies in the PD-1 and PD-L1 Drug market?

Top companies include Merck, Bristol Myers Squibb, and Roche, which are driving innovation and growth.

What are the future opportunities in the PD-1 and PD-L1 Drug market?

Future opportunities include emerging markets, increasing use of combination therapies, and growing demand for personalized medicine.

How is technology impacting the PD-1 and PD-L1 Drug market?

Technology is driving advancements in drug development, manufacturing, and distribution, improving efficiency and reducing costs.

What is the current regulatory landscape for the PD-1 and PD-L1 Drug market?

The regulatory landscape is evolving, with increasing focus on safety, efficacy, and quality, driving the need for compliance.

What is the expected future outlook for the PD-1 and PD-L1 Drug market?

The future outlook is positive, driven by growing demand, increasing adoption, and ongoing innovation in the market.

Global PD-1 and PD-L1 Drug Market Value Is Forecast To Reach By 2034 With CAGR

PD-1 and PD-L1 Drug by Application (Liver Cancer, Esophageal Cancer, Nasal Cancer, Stomach Cancer, Other), by Types (PD-1 Monoclonal Antibody, PD-L1 Monoclonal Antibody), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $12400 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $12400 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

PD-1 and PD-L1 Drug Market Overview

The PD-1 and PD-L1 Drug market refers to the industry focused on developing and marketing therapies that target the programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) pathways to treat various types of cancer. As the PD-1 and PD-L1 Drug market size is expected to grow significantly, driven by a strong growth outlook and optimistic market forecast, it is essential to understand the key drivers and trends shaping the industry expansion. The scope of this market encompasses a range of immuno-oncology therapies, including monoclonal antibodies and combination treatments, which are transforming the landscape of cancer treatment. The current PD-1 and PD-L1 Drug market size is approximately $25 billion, with a projected CAGR of around 15% from 2026 to 2033.

Loading chart…

The PD-1 and PD-L1 Drug market is being shaped by several key forces, including technology shifts towards more targeted and effective therapies, regulatory approvals that are facilitating the entry of new treatments, and changing consumer behavior as patients become more informed and demanding of innovative treatments. The largest region for PD-1 and PD-L1 Drugs is currently North America, while the fastest-growing region is Asia-Pacific, driven by increasing cancer incidence and improving healthcare infrastructure. As the market continues to evolve, it is essential for stakeholders to stay informed about the latest trends and developments to remain competitive and capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	12.40 billion
Revenue forecast in 2033	32.50 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bristol Myers Squibb; Merck & Co., Inc.; F. Hoffmann -La Roche Ltd; AstraZeneca; Sanofi; Pfizer Inc; Lilly; Novartis AG; GSK; Junshi Biosciences; Akeso, Inc; BeiGene; Innovent; Jiangsu Hengrui Medicine Co.,Ltd; Cstone; Henlius; Simcere Pharmaceutical Group Limited
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The PD-1 and PD-L1 Drug market is poised for significant growth, driven by increasing demand for effective cancer treatments. The market dynamics are influenced by various factors, including technological advancements, regulatory approvals, and shifting consumer preferences.

Growth Drivers2 items

The rising prevalence of cancer and the growing need for targeted therapies are driving the PD-1 and PD-L1 Drug market size, with a projected growth forecast of over 10% in the next five years.

Advances in immuno-oncology research and the development of combination therapies are further fueling the growth of the PD-1 and PD-L1 Drug market, as players focus on improving treatment outcomes and expanding their product portfolios.

Restraints2 items

High development costs and stringent regulatory requirements are hindering the growth of the PD-1 and PD-L1 Drug market, as companies face significant challenges in bringing new products to market.

The presence of established players and the resulting competition are also limiting the growth of the PD-1 and PD-L1 Drug market, as new entrants struggle to gain traction and market share.

Opportunities2 items

The increasing focus on personalized medicine and targeted therapies presents significant opportunities for growth in the PD-1 and PD-L1 Drug market, as companies develop treatments tailored to specific patient populations.

Emerging markets and expanding healthcare infrastructure in developing economies are also creating new opportunities for players in the PD-1 and PD-L1 Drug market, as they look to tap into growing demand for cancer treatments.

Challenges2 items

The management of adverse events and toxicities associated with PD-1 and PD-L1 inhibitors remains a significant challenge, as companies work to optimize treatment regimens and minimize side effects.

The growth forecast of the PD-1 and PD-L1 Drug market is also subject to macroeconomic factors, including fluctuations in global economic conditions and healthcare spending, which can impact market size and demand.

Market Segmentation

Loading chart…

The PD-1 and PD-L1 Drug market can be segmented based on Application, which includes subtypes such as melanoma, lung cancer, and kidney cancer. This segmentation category contributes to the overall market size by highlighting the specific disease areas where PD-1 and PD-L1 drugs are most effective. Understanding the application segment is crucial for market players to develop targeted therapies and tap into the growing demand for immunotherapies.

Another key segmentation category for the PD-1 and PD-L1 Drug market is Types, which includes subtypes such as monoclonal antibodies and bispecific antibodies. This segmentation category is essential for understanding the PD-1 and PD-L1 Drug segmentation landscape, as it reveals the different mechanisms of action and molecular targets that are being exploited to develop innovative therapies. By analyzing the types segment, market players can identify opportunities for differentiation and innovation in the competitive landscape.

PD-1 and PD-L1 Drug Segmentation Breakdown9 items

Application

Liver Cancer

Esophageal Cancer

Nasal Cancer

Stomach Cancer

Other

Types

PD-1 Monoclonal Antibody

PD-L1 Monoclonal Antibody

Regional Insights

Loading chart…

The PD-1 and PD-L1 Drug market growth is anticipated to be driven by various factors across different regions. North America is the largest region, accounting for approximately 40% of the market share, driven by factors such as high adoption rates, favorable policies, and significant investments in research and development. Key drivers for North America include a mature ecosystem, high demographics of cancer patients, and advanced infrastructure.

The fastest-growing region is expected to be Asia Pacific, driven by increasing demographics, growing infrastructure, and rising investments in the healthcare sector. Europe is also expected to contribute significantly to the PD-1 and PD-L1 Drug market growth, with key drivers including favorable policies, high adoption rates, and a mature ecosystem. Latin America and Middle East & Africa are expected to have a relatively smaller share, but are still expected to experience significant growth driven by increasing adoption and investments.

Regional Forecast5 items

North America: driven by high adoption rates, favorable policies, and significant investments

Europe: driven by favorable policies, high adoption rates, and a mature ecosystem

Asia Pacific: driven by increasing demographics, growing infrastructure, and rising investments

Latin America: driven by increasing adoption and investments

Middle East & Africa: driven by increasing adoption and investments

Competitive Landscape

The PD-1 and PD-L1 Drug market exhibits a moderately consolidated structure, driven by a mix of global players and local companies. The PD-1 and PD-L1 Drug competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on premium pricing and innovation, while local companies emphasize affordability and regional distribution networks.

Companies employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies must develop unique value propositions, leveraging technology, service models, channel strength, customization, and cost advantages. The following companies illustrate diverse strategic focuses:

Bristol Myers Squibb: regional expansion

Merck & Co., Inc.: innovation pipeline

F. Hoffmann -La Roche Ltd: premium pricing

AstraZeneca: vertical integration

Sanofi: local manufacturing

Pfizer Inc: OEM tie-ups

Key PD-1 and PD-L1 Drug Companies17 items

Bristol Myers Squibb

Merck & Co., Inc.

F. Hoffmann -La Roche Ltd

AstraZeneca

Sanofi

Pfizer Inc

Lilly

Novartis AG

GSK

Junshi Biosciences

Akeso, Inc

BeiGene

Innovent

Jiangsu Hengrui Medicine Co.,Ltd

Cstone

Henlius

Simcere Pharmaceutical Group Limited

Market Ecosystem

The PD-1 and PD-L1 Drug ecosystem encompasses a complex network of stakeholders, spanning upstream technology providers and suppliers to downstream end users. Value is created and captured through the development, manufacturing, and distribution of these drugs, which are used to treat various types of cancer. The ecosystem can be broadly divided into three segments: upstream, midstream, and downstream, with each segment comprising different types of participants who interact and influence one another.

Raw material/component suppliers — providing active pharmaceutical ingredients

OEMs / manufacturers — producing PD-1 and PD-L1 drugs

Technology providers — developing new formulations and delivery systems

System integrators / EPCs — integrating drugs into treatment regimens

Distributors / channel partners — delivering drugs to healthcare providers

Service providers / after-sales — offering patient support and monitoring services

Regulators/standards bodies — overseeing drug approvals and safety standards

The flow of value through the PD-1 and PD-L1 Drug ecosystem is influenced by various control points, including regulatory approvals, reimbursement policies, and patient demand. Dependency risks, such as limited access to raw materials or manufacturing capacity constraints, can impact the production and supply of these drugs. Furthermore, partnerships between participants, such as collaborations between technology providers and manufacturers, can facilitate the development of new treatments and improve patient outcomes. A thorough understanding of the PD-1 and PD-L1 Drug ecosystem, through a value chain analysis, is essential for identifying opportunities and challenges in this complex and evolving market.

Recent Industry Insights

The PD-1 and PD-L1 Drug industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between Merck and AstraZeneca, have focused on enhancing the efficacy of combination therapies. Additionally, mergers and acquisitions, like the Bristol Myers Squibb and Celgene deal, have led to the expansion of product portfolios. Several product launches have also taken place, including the introduction of new checkpoint inhibitors that have shown promising results in clinical trials.

Regulatory changes, such as the FDA's approval of new indications for existing drugs, have further propelled the growth of the PD-1 and PD-L1 Drug market. Furthermore, a shift in consumer trends towards personalized medicine has led to increased demand for targeted therapies. Funding rounds and expansions, including significant investments in research and development, are expected to drive innovation and growth in the industry.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the PD-1 and PD-L1 Drug market outlook. The market exhibits high attractiveness due to its significant growth potential and increasing demand for immunotherapy treatments. The competitive intensity is moderate, with key players dominating the market, but new entrants are expected to increase competition. The long-term outlook is promising, driven by ongoing innovation and rising incidence of cancer. The innovation landscape is rapidly evolving, with a focus on combination therapies and biomarker development. However, the demand-supply balance is a concern, with potential shortages of certain treatments. Key risk factors include regulatory challenges, pricing pressures, and patent expirations.

12 items

1. Executive Summary

2. PD-1 and PD-L1 Drug Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global PD-1 and PD-L1 Drug Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global PD-1 and PD-L1 Drug Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global PD-1 and PD-L1 Drug Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global PD-1 and PD-L1 Drug Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global PD-1 and PD-L1 Drug Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global PD-1 and PD-L1 Drug Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global PD-1 and PD-L1 Drug Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global PD-1 and PD-L1 Drug Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global PD-1 and PD-L1 Drug Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global PD-1 and PD-L1 Drug Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global PD-1 and PD-L1 Drug Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global PD-1 and PD-L1 Drug Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global PD-1 and PD-L1 Drug Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global PD-1 and PD-L1 Drug Market Competition by Key Manufacturers

9.1. Global PD-1 and PD-L1 Drug Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global PD-1 and PD-L1 Drug: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Bristol Myers Squibb

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Merck & Co., Inc.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. F. Hoffmann -La Roche Ltd

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. AstraZeneca

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Sanofi

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Pfizer Inc

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Lilly

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Novartis AG

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. GSK

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Junshi Biosciences

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Akeso, Inc

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. BeiGene

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Innovent

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Jiangsu Hengrui Medicine Co.,Ltd

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Cstone

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Henlius

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Simcere Pharmaceutical Group Limited

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global PD-1 and PD-L1 Drug Market

Figure 4: Global PD-1 and PD-L1 Drug Market: Drivers

Figure 5: Global PD-1 and PD-L1 Drug Market: Challenges

Figure 6: Global PD-1 and PD-L1 Drug Market: Trends

Figure 7: Global PD-1 and PD-L1 Drug Market: Opportunity

Figure 8: Global PD-1 and PD-L1 Drug Market: Restraint

Figure 9: Global PD-1 and PD-L1 Drug Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global PD-1 and PD-L1 Drug Market Value (USD Million) By Region

Figure 19: Global PD-1 and PD-L1 Drug Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global PD-1 and PD-L1 Drug Market Value (USD Million) By Region

Figure 27: Global PD-1 and PD-L1 Drug Market Share (%) By: Regions (2032)

Figure 28: Global PD-1 and PD-L1 Drug Market Volume (K) By Region

Figure 29: Global PD-1 and PD-L1 Drug Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global PD-1 and PD-L1 Drug Market Value (USD Million) By Region

Figure 37: Global PD-1 and PD-L1 Drug Market Share (%) By: Regions (2032)

Figure 38: Global PD-1 and PD-L1 Drug Market Volume (K) By Region

Figure 39: Global PD-1 and PD-L1 Drug Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

129 items

Table 1: Market Segmentation Analysis

Table 2: Global PD-1 and PD-L1 Drug Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global PD-1 and PD-L1 Drug Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global PD-1 and PD-L1 Drug Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global PD-1 and PD-L1 Drug Market Value (USD Million) By Region

Table 14: Global PD-1 and PD-L1 Drug Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global PD-1 and PD-L1 Drug Market Volume (K) By Region

Table 31: Global PD-1 and PD-L1 Drug Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global PD-1 and PD-L1 Drug Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global PD-1 and PD-L1 Drug Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global PD-1 and PD-L1 Drug Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Bristol Myers Squibb Basic Information And Sales Area

Table 52: Bristol Myers Squibb. Products Portfolio

Table 53: Merck & Co., Inc. Basic Information And Sales Area

Table 54: Merck & Co., Inc.. Products Portfolio

Table 55: F. Hoffmann -La Roche Ltd Basic Information And Sales Area

Table 56: F. Hoffmann -La Roche Ltd. Products Portfolio

Table 57: AstraZeneca Basic Information And Sales Area

Table 58: AstraZeneca. Products Portfolio

Table 59: Sanofi Basic Information And Sales Area

Table 60: Sanofi. Products Portfolio

Table 61: Pfizer Inc Basic Information And Sales Area

Table 62: Pfizer Inc. Products Portfolio

Table 63: Lilly Basic Information And Sales Area

Table 64: Lilly. Products Portfolio

Table 65: Novartis AG Basic Information And Sales Area

Table 66: Novartis AG. Products Portfolio

Table 67: GSK Basic Information And Sales Area

Table 68: GSK. Products Portfolio

Table 69: Junshi Biosciences Basic Information And Sales Area

Table 70: Junshi Biosciences. Products Portfolio

Table 71: Akeso, Inc Basic Information And Sales Area

Table 72: Akeso, Inc. Products Portfolio

Table 73: BeiGene Basic Information And Sales Area

Table 74: BeiGene. Products Portfolio

Table 75: Innovent Basic Information And Sales Area

Table 76: Innovent. Products Portfolio

Table 77: Jiangsu Hengrui Medicine Co.,Ltd Basic Information And Sales Area

Table 78: Jiangsu Hengrui Medicine Co.,Ltd. Products Portfolio

Table 79: Cstone Basic Information And Sales Area

Table 80: Cstone. Products Portfolio

Table 81: Henlius Basic Information And Sales Area

Table 82: Henlius. Products Portfolio

Table 83: Simcere Pharmaceutical Group Limited Basic Information And Sales Area

Table 84: Simcere Pharmaceutical Group Limited. Products Portfolio

Table 85: Global Market Value (USD Million) (2025-2032) By Application

Table 86: Global Market Share (%) By Application (2032)

Table 87: Global Market Value (USD Million) (2025-2032) By Types

Table 88: Global Market Share (%) By Types (2032)

Table 89: Global Market Volume (K) (2025-2032) By Application

Table 90: Global Market Share (%) By Application (2032)

Table 91: Global Market Volume (K) (2025-2032) By Types

Table 92: Global Market Share (%) By Types (2032)

Table 93: Global PD-1 and PD-L1 Drug Market Value (USD Million) By Region

Table 94: Global PD-1 and PD-L1 Drug Market Share (%) By Region (2025-2032)

Table 95: North America Market Value (USD Million) (2025-2032) By Country

Table 96: North America Market Value (USD Million) (2025-2032) By Application

Table 97: North America Market Value (USD Million) (2025-2032) By Types

Table 98: Europe Market Value (USD Million) (2025-2032) By Country

Table 99: Europe Market Value (USD Million) (2025-2032) By Application

Table 100: Europe Market Value (USD Million) (2025-2032) By Types

Table 101: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 102: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 103: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 104: South America Market Value (USD Million) (2025-2032) By Country

Table 105: South America Market Value (USD Million) (2025-2032) By Application

Table 106: South America Market Value (USD Million) (2025-2032) By Types

Table 107: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 108: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 109: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 110: Global PD-1 and PD-L1 Drug Market Volume (K) By Region

Table 111: Global PD-1 and PD-L1 Drug Market Share (%) By Region (2025-2032)

Table 112: North America Market Volume (K) (2025-2032) By Country

Table 113: North America Market Volume (K) (2025-2032) By Application

Table 114: North America Market Volume (K) (2025-2032) By Types

Table 115: Europe Market Volume (K) (2025-2032) By Country

Table 116: Europe Market Volume (K) (2025-2032) By Application

Table 117: Europe Market Volume (K) (2025-2032) By Types

Table 118: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 119: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 120: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 121: South America Market Volume (K) (2025-2032) By Country

Table 122: South America Market Volume (K) (2025-2032) By Application

Table 123: South America Market Volume (K) (2025-2032) By Types

Table 124: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 125: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 126: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 127: Research Programs/Design For This Report

Table 128: Key Data Information From Secondary Sources

Table 129: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

PD-1 and PD-L1 Drug Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.40 billion
Revenue forecast in 2033	32.50 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bristol Myers Squibb; Merck & Co., Inc.; F. Hoffmann -La Roche Ltd; AstraZeneca; Sanofi; Pfizer Inc; Lilly; Novartis AG; GSK; Junshi Biosciences; Akeso, Inc; BeiGene; Innovent; Jiangsu Hengrui Medicine Co.,Ltd; Cstone; Henlius; Simcere Pharmaceutical Group Limited
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

The presence of established players and the resulting competition are also limiting the growth of the PD-1 and PD-L1 Drug market, as new entrants struggle to gain traction and market share.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

PD-1 and PD-L1 Drug Segmentation Breakdown9 items

Application

Liver Cancer

Esophageal Cancer

Nasal Cancer

Stomach Cancer

Other

Types

PD-1 Monoclonal Antibody

PD-L1 Monoclonal Antibody

Regional Insights

Loading chart…

Regional Forecast5 items

North America: driven by high adoption rates, favorable policies, and significant investments

Europe: driven by favorable policies, high adoption rates, and a mature ecosystem

Asia Pacific: driven by increasing demographics, growing infrastructure, and rising investments

Latin America: driven by increasing adoption and investments

Middle East & Africa: driven by increasing adoption and investments

Competitive Landscape

Bristol Myers Squibb: regional expansion

Merck & Co., Inc.: innovation pipeline

F. Hoffmann -La Roche Ltd: premium pricing

AstraZeneca: vertical integration

Sanofi: local manufacturing

Pfizer Inc: OEM tie-ups

Key PD-1 and PD-L1 Drug Companies17 items

Bristol Myers Squibb

Merck & Co., Inc.

F. Hoffmann -La Roche Ltd

AstraZeneca

Sanofi

Pfizer Inc

Lilly

Novartis AG

GSK

Junshi Biosciences

Akeso, Inc

BeiGene

Innovent

Jiangsu Hengrui Medicine Co.,Ltd

Cstone

Henlius

Simcere Pharmaceutical Group Limited

Market Ecosystem

Raw material/component suppliers — providing active pharmaceutical ingredients

OEMs / manufacturers — producing PD-1 and PD-L1 drugs

Technology providers — developing new formulations and delivery systems

System integrators / EPCs — integrating drugs into treatment regimens

Distributors / channel partners — delivering drugs to healthcare providers

Service providers / after-sales — offering patient support and monitoring services

Regulators/standards bodies — overseeing drug approvals and safety standards

Recent Industry Insights

Analyst Overview

Table of Contents